Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis

NCT ID: NCT01685229

Last Updated: 2024-07-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

198 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-01

Study Completion Date

2015-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-market study aims to compare health outcomes for Chronic Rhinosinusitis (CRS) patients treated with balloon sinus dilation (BSD) versus continued medical management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Balloon Sinus Dilation

Subjects with chronic sinusitis electing to have a balloon sinus dilation

Balloon sinus dilation

Intervention Type DEVICE

Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.

Medical Management

Subjects with chronic sinusitis electing to continue with medical therapy

Medical Management

Intervention Type DRUG

Subjects who select to continue on medical management rather than have a BSD procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Balloon sinus dilation

Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.

Intervention Type DEVICE

Medical Management

Subjects who select to continue on medical management rather than have a BSD procedure.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acclarent Balloon Sinuplasty System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females aged 19 or greater
* Diagnosis of Chronic Rhinosinusitis (CRS)
* Failure of appropriate medical management
* Radiographic evidence of inflammation of the paranasal sinuses
* Surgical candidate
* Willing and able to read and sign the Informed Consent Form and remain compliant with the protocol and study procedures
* Able to read and understand English

Exclusion Criteria

* Not suitable for balloon dilation for all peripheral sinuses that require treatment
* Clinically significant illness that may interfere with the evaluation of the study
* Patients involved in other clinical studies 30 days prior to study
* Pregnant or lactating females
* Patients unable to adhere to follow-up schedule or protocol requirements
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acclarent

INDUSTRY

Sponsor Role collaborator

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Spencer Payne, MD

Role: PRINCIPAL_INVESTIGATOR

University of Virginia

Christopher Melroy, MD

Role: PRINCIPAL_INVESTIGATOR

Georgia Nasal and Sinus Institute

Boris Karanfilov, MD

Role: PRINCIPAL_INVESTIGATOR

Ohio Sinus Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Denver, Colorado, United States

Site Status

Miami, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Savannah, Georgia, United States

Site Status

Vidalia, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Rockford, Illinois, United States

Site Status

South Bend, Indiana, United States

Site Status

Louisville, Kentucky, United States

Site Status

Neptune City, New Jersey, United States

Site Status

Dublin, Ohio, United States

Site Status

Frisco, Texas, United States

Site Status

McKinney, Texas, United States

Site Status

Plano, Texas, United States

Site Status

Charlottesville, Virginia, United States

Site Status

Norfolk, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Beaver Dam, Wisconsin, United States

Site Status

Wauwatosa, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPR005028

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nebulized Nasal Steroids
NCT07270302 NOT_YET_RECRUITING PHASE1/PHASE2
th2 Modulation CRSwNP
NCT06107101 NOT_YET_RECRUITING PHASE4